Current Takeaway
ME/CFS is established as a serious, multi-systemic, biologically grounded illness. Since the 2015 IOM report established a tightened clinical case definition around post-exertional malaise, unrefreshing sleep, and cognitive or orthostatic symptoms, large-scale epidemiology and registry studies have clarified the disease’s massive socioeconomic burden and persistent care gaps. In the United States, survey data indicates that 1.5% of adults have received a diagnosis, with the critical caveat that nearly half of those reporting a “past” diagnosis still experience active symptoms and functional impairment. In New Zealand, nationwide registry data documents severe socioeconomic disadvantage, including employment rates under 20% and significant barriers to obtaining disability support services. These challenges are compounded by healthcare fragmentation and “statistical invisibility” due to missing diagnostic codes, as highlighted in service reviews, which obstruct patient tracking and service capacity planning.
Recent large-scale symptom-clustering and factor analysis work has successfully stratified patients into distinct clinical subgroups. Analysis of the UK DecodeME cohort of over 19,000 participants identified high- and low-symptom-burden subgroups, linking infectious onset to higher long-term severity, though without finding genome-wide genetic predictors. Other factor analyses confirm that patient-reported symptoms group into coherent biological dimensions (brain, autonomic, gut-immune), with sex-stratified models revealing that female sex hormones dynamically modulate immune symptoms (such as flu-like complaints in premenopausal women) but not gastrointestinal pathways. Standardized symptom measurement has also advanced with the Rasch-validated TIMES scale, mapping a severe cumulative multi-system burden where cognitive symptoms are ranked as the most troublesome.
National research and care infrastructure has grown substantially with new large-scale funding and specialized networks. In Europe, the launching of the €7.5 million DISCOVER-ME consortium aims to standardize biobank protocols across 20+ institutions to validate multi-system biomarkers. In Germany, the BMG-funded PEDNET-LC network has established care pathways and a centralized pediatric registry, complementing childhood cohort data showing that pediatric post-COVID symptom persistence correlates stepwise with initial infection severity. However, therapeutic evidence remains preliminary: while pilot updates from the Cohen Center report safety for home-use magnetic therapy and long-term antiviral case series, a major controlled trial of specialized inpatient rehabilitation in Germany showed no significant physical function benefit over standard GP care.
Why This Matters
The precision of a case definition shapes every downstream study. Cohorts recruited under the 1994 Fukuda criteria, the Canadian Consensus Criteria, and the 2015 IOM criteria differ substantially in symptom severity and biological signal, which complicates comparisons between studies and between funders. Epidemiological work matters for the same reason: if the patient population captured by registries skews toward those with diagnostic access, prevalence estimates undercount the true burden and resource allocation follows those biased numbers.
Measurement tools directly affect whether clinical trials can detect real change. The absence of a validated, psychometrically grounded symptom scale has historically made it hard to compare trial arms or aggregate data across sites. New instruments developed with patients, like the TIMES scale, and new methodological frameworks accounting for chronobiology and sex-hormone cycles represent substantive infrastructure improvements, even when they produce no treatment findings on their own.
State of Evidence
- Established: ME/CFS meets clinical criteria for a severe, chronic, multi-systemic illness. PEM, unrefreshing sleep, and cognitive or autonomic symptoms anchor all major case definitions. International medical societies and clinical consensus guidelines (IDSA, ERJ) define infection-associated chronic conditions (IACCs) and mandate pacing while contraindicating graded exercise therapy. The massive socioeconomic impact, including extremely low employment and high polypharmacy, is documented at the national registry level. Clinical symptom profiles consistently group into statistically distinct biological factors (brain, gut, immune, autonomic) across large cohorts. Gastrointestinal comorbidity is quantitatively elevated, with meta-analytic data demonstrating a 37% pooled prevalence and a seven-fold increased odds of irritable bowel syndrome (OR 7.20, 95% CI 2.77–18.76) in ME/CFS, though the direction of association remains unresolved.
- Plausible but early: ME/CFS symptom severity can be stratified into distinct high- and low-symptom-burden subgroups linked to infectious triggers. Structural equation modeling demonstrates sex- and menopause-specific latent symptom structures, with female sex hormones dynamically modulating immune (flu-like) symptoms but not gastrointestinal pathways. Large-scale epidemiological surveys show adolescent CFS prevalence correlates with academic stage and physical endurance deficits, while participatory research frameworks (CureME, Deutsche Gesellschaft für ME/CFS) optimize biobanking and trial co-design. In children, post-COVID symptom persistence correlates with initial infection severity.
- Not established: Any single objective biomarker or diagnostic test that reliably identifies ME/CFS across populations. Genome-wide significant genetic variants that differentiate clinical severity subgroups. Electronic health record (EHR) diagnostic billing codes as sensitive or complete metrics for population prevalence, due to widespread diagnostic undercoding and billing delays.
- Key limitations: Multi-country network cohort analyses relying on ICD billing codes in electronic health records undercount ME/CFS and dysautonomia cases due to diagnostic delays and coding stigma. Standard patient-reported outcome measures (PROMs) frequently miss post-exertional malaise and cognitive fluctuations, introducing measurement error into clinical trials. Many large cohort analyses rely on self-reported online surveys, introducing selection biases and lacking objective physiological measures. A growing share of the post-viral characterization literature relies on broad Post-COVID Condition (PASC) or registry cohorts without ME/CFS case definitions or standardized post-exertional malaise measurement, meaning prevalence figures, symptom distributions, and socioeconomic burden estimates from these cohorts do not transfer directly to criteria-defined ME/CFS.
Timeline
2015-02-10 - IOM report proposes SEID criteria and legitimises ME/CFS as a systemic disease
The Institute of Medicine commissioned a 15-member expert committee to resolve the longstanding proliferation of conflicting case definitions. After reviewing literature back to 1950 and taking testimony from patients and researchers, the committee proposed three required core symptoms—substantially reduced activity lasting more than six months with profound new-onset fatigue not alleviated by rest, post-exertional malaise, and unrefreshing sleep—plus at least one of cognitive impairment or orthostatic intolerance. The committee also concluded that neither of the existing names served the illness well, proposing “systemic exertion intolerance disease” (SEID) as an alternative, a name that has not been widely adopted but whose rationale—centering exertion intolerance—has influenced subsequent clinical guidance. The report simultaneously flagged that between 84 and 91 percent of patients remained undiagnosed and that the research funding base was inadequate to support subgroup work or natural history studies. It remains the most widely cited modern framework for what a minimum case definition must include.
Sources:
2024-11-20 - DISCOVER-ME consortium launches with €7.5 million EU Horizon Europe funding
The DISCOVER-ME project was announced as the first major EU-funded initiative specifically targeting biological stratification of ME/CFS patients, bringing together 21 international partners across Europe and North America. Using high-throughput multi-omics approaches—including genomics, proteomics, metabolomics, and microbiome analysis—the consortium aims to identify distinct molecular patient subgroups that differ in disease mechanisms and potentially in treatment response. The project draws on existing biobanks and harmonized clinical data to build a large enough cohort to find consistent biological signals within a heterogeneous patient population. No stratification findings have been reported yet; the first outputs expected are standardized biobanking protocols and a map of the most informative molecular markers for classification. Success depends heavily on rigorous data harmonization across multiple sites and on pre-stratifying samples by disease severity and PEM status to reduce biological noise.
Sources:
2025-03-24 - Norwegian registry sampling study shows socioeconomic bias in official ME/CFS records
A study comparing Norwegian ICD-10 G93.3 registry data with an online peer-referral sampling method (respondent-driven sampling, RDS) found that the likelihood of receiving a formal ME/CFS diagnosis was influenced by sociodemographic factors even after controlling for symptom severity. Patients with higher socioeconomic status and better access to specialist care were more likely to appear in administrative registers, meaning standard registry-based prevalence estimates exclude a substantial portion of the actual patient population. The RDS approach successfully reached a broader and more clinically homogeneous cohort using validated DePaul University algorithms against the Canadian Consensus Criteria. A residual limitation is that severely ill patients who are not active online remain difficult to reach even by peer referral. The finding is methodologically consequential: any epidemiological study that relies on national coding databases alone risks systematically undercounting the burden of illness and producing skewed demographic profiles of who ME/CFS affects.
Sources:
2025-08-24 - German clinical practice guide formalises management approach for primary care
The Deutsche Gesellschaft für ME/CFS published a comprehensive practice guide for German-speaking clinicians, synthesizing international diagnostic criteria—IOM, Canadian Consensus Criteria, NICE 2021—into a practical framework for general practitioners. The guide explicitly codes ME/CFS as a severe neuroimmunological disease with typical diagnostic delays of six to seven years in Germany, and notes that 10 to 20 percent of patients with post-COVID syndrome develop ME/CFS. It organises management around three pillars: energy management through pacing to prevent PEM, symptomatic off-label pharmacotherapy for the most burdensome symptoms, and diagnosis and treatment of common comorbidities including POTS, MCAS, and small-fiber neuropathy. Graded exercise therapy is explicitly listed as contraindicated due to risk of severe deterioration. The guide does not introduce new primary data but reflects the consolidation of expert consensus at the level of national specialty societies, which is significant for how quickly guideline-consistent care diffuses into routine clinical encounters.
Sources:
2025-12-01 - Review positions ME/CFS within a cluster of multisystem chronic illnesses sharing care gaps
A review from New Zealand compared the clinical and biological features of ME/CFS, Long COVID, fibromyalgia, Ehlers-Danlos syndrome, and multiple sclerosis, arguing that shared disruptions in the gut-immune-brain axis have been managed in clinical isolation at a cost to all patient groups. The comparison with MS is instructive: while MS patients have access to structured multidisciplinary clinics, clear disease-modifying therapy pathways, and well-defined disability and social support routes, ME/CFS and Long COVID patients face much higher systemic barriers to formal recognition, financial assistance, and employment protection. The authors identify the absence of an accessible molecular diagnostic test as the primary obstacle to social recognition for ME/CFS and Long COVID specifically, because clinician recognition of a diagnosis—required for support access—depends on tests that do not yet exist. The argument does not advance new biological data but maps the care infrastructure gap against a model that does work, making the deficit visible in comparative terms.
Sources:
2025-12-08 - Germany announces €500 million National Decade Against Post-Infectious Diseases
Germany committed €500 million over the period 2026–2036 to a dedicated national research program targeting Long COVID, ME/CFS, and related post-viral conditions under the framing of a “National Decade Against Post-Infectious Diseases.” The announcement, reported in Nature, describes plans for the National Clinical Study Group (NKSG) to accelerate clinical trials for prioritized off-label candidates and to build longitudinal research infrastructure that standard short-term funding cycles have not supported. The scale is notable: at roughly $582 million, it is larger than any single national government commitment to this disease cluster to date. Long COVID is estimated to cost the global economy approximately $1 trillion annually, providing the economic framing for the investment. A key open question—raised by both patient advocates and researchers interviewed for the Nature piece—is whether the funds will prioritize mechanistic biomedical inquiry or flow toward psychosocial treatment models that patient groups consider harmful or insufficiently grounded.
Sources:
2025-12-09 - Systematic review updates diagnostic and management guidance in light of Long COVID overlap
A systematic review published in the Journal of Translational Medicine synthesized ME/CFS diagnostic criteria, pathophysiology, and management through August 2025, explicitly situating the illness within the broader post-viral landscape that Long COVID has expanded. The review confirmed that diagnosis still rests on clinical criteria centred on PEM and cognitive dysfunction, because definitive biomarkers remain absent. It identified immune dysregulation, oxidative stress, mitochondrial dysfunction, and neuroinflammation as the leading candidate pathologies, while concluding that graded exercise therapy is contraindicated. On management, the review highlights activity pacing as the primary non-pharmacological approach and calls for future work to identify combination therapies targeting multiple pathways simultaneously. The practical implication is that the review provides a current clinical consensus document anchored in indexed literature, which supporting how primary care clinicians can update their approach without waiting for biomarker-based diagnostic tools.
Sources:
2025-12-10 - Imperial College’s Rosetta Stone study launches to compare ME/CFS and Long COVID immunology
Imperial College London announced £1.1 million in funding for the Rosetta Stone study, which will perform a direct side-by-side molecular comparison of 250 people with ME/CFS and 250 people with Long COVID alongside matched healthy controls. Blood, stool, and saliva samples will be analysed using high-resolution immunological profiling, with symptom data collected via the ELAROS smartphone app. The project draws on the UK ME/CFS Biobank and integrates with the existing DecodeME genetic cohort and the NIHR WILCO Long COVID study, building connectivity across the major UK patient resources. The stated goal is to identify shared immunological pathways—the “Rosetta Stone” key—that could explain overlapping post-infectious disability, and to distinguish what is shared from what is disease-specific. No findings are available from this announcement; the three-year data collection and analysis phase is the focus.
Sources:
2026-01-09 - Canadian cohort study identifies predictors of symptom worsening after vaccination in Long COVID
A multicenter cohort study of 476 Long COVID patients from 33 Canadian emergency departments found that 28.8 percent reported symptom deterioration after receiving a SARS-CoV-2 vaccine dose more than 90 days after initial infection. Two factors were significantly associated with this pattern: receiving the Moderna mRNA-1273 vaccine and having a persistent cough three months after initial infection. Sex and age were not significant predictors. The study is relevant to clinical characterization because it identifies a clinically recognized subgroup experience—post-vaccination symptom worsening—and attaches it to measurable pre-vaccination characteristics, which matters for patient counselling and for understanding how immune activation interacts with ongoing post-viral illness. Limitations include self-reported symptom data, absence of a non-vaccinated control arm, and the inability to assess whether reported deterioration was temporary or persistent.
Sources:
2026-01-14 - MELLOW study protocol introduces chronobiology-aligned multi-omics design for female patients
Researchers at the University of Melbourne published the protocol for the MELLOW study, a prospective longitudinal investigation of how menstrual and diurnal biological rhythms shape molecular and physiological markers in reproductive-aged women with ME/CFS and Long COVID. The study uses multi-omics including genomics, proteomics, metabolomics, and steroidomics combined with wearable physiological monitoring and symptom tracking timed across the menstrual cycle. The methodological significance is that most prior ME/CFS biomarker studies have not controlled for hormonal phase, which introduces variability that can mask real signals or produce false positives in female cohorts—the majority of ME/CFS patients. This is a protocol paper, so no biological results are yet available. If the study performs as designed, it could clarify why female sex is a primary risk factor and produce more reproducible hormonal and immune biomarker profiles than unstratified prior work.
Sources:
2026-01-16 - Dutch Lifelines cohort study identifies “general malaise” as a transdiagnostic symptom dimension
An analysis of 108,418 adult participants in the Dutch Lifelines Cohort Study used factor analysis on 30 symptoms of major depressive disorder, generalized anxiety disorder, ME/CFS, fibromyalgia, and irritable bowel syndrome to identify five distinct symptom dimensions: Depression, Anxiety, IBS, Musculoskeletal Pain, and General Malaise. Symptoms of ME/CFS and fibromyalgia did not form their own isolated categories, but instead loaded onto the general malaise (characterized by concentration difficulties, fatigue, and unrefreshing sleep) and musculoskeletal pain dimensions. Chronic stress was the only risk factor significantly associated with all five dimensions, suggesting a shared pathway involving stress response system dysregulation. This validates that the core disabling symptoms of ME/CFS represent a highly real, measurable “general malaise” dimension that is distinct from primary depression and anxiety, even while showing high transdiagnostic comorbidity. However, this study relies entirely on cross-sectional self-reported survey data rather than clinician-verified diagnoses, which prevents establishing causal relationships or tracking individual trajectories over time.
Sources:
2026-02-01 - Lancet Americas longitudinal cohort maps symptom persistence over 12 months in US PASC patients
A national US cohort study using the COPE Initiative, which tracked more than 11,000 adults, reported that fatigue, brain fog, and shortness of breath were not only common after SARS-CoV-2 infection but showed persistent or fluctuating trajectories over 12 months in a substantial proportion of PASC patients. The study found that pre-existing conditions and absence of booster vaccination were associated with longer recovery and higher symptom burden, while vaccination and early antiviral treatment were associated with reduced long-term load. The characterisation of PASC as a condition with fluctuating rather than uniformly declining symptoms over a year is relevant to how clinicians explain the illness trajectory to patients and to how clinical trials define endpoints: a single follow-up point at three or six months may miss the full course. The study does not address ME/CFS diagnostic criteria directly but describes the cohort dynamics that will appear upstream of formal ME/CFS diagnosis in many post-COVID patients.
Sources:
2026-02-17 - TIMES scale completes first-phase psychometric validation for ME/CFS symptom measurement
The Index of Myalgic Encephalomyelitis Symptoms (TIMES) completed Rasch analysis validation in a two-cohort development process involving 721 and then 354 participants with ME/CFS recruited primarily in the UK. The instrument maps 85 symptom items across eight domains, and the Rasch analysis confirmed that a four-point frequency and severity response format outperformed the original five-point version. Neurological and autonomic symptom subscales were validated as internally consistent and stable. The clinical significance is that validated, psychometrically grounded symptom measurement matters for clinical trials: without stable instruments, treatment effects are difficult to detect or compare across sites. TIMES fills a gap that has constrained ME/CFS trial design, because many symptom checklists in prior studies lacked formal psychometric properties. The companion reliability paper and international validation remain pending, so the current evidence supports construct and content validity in a UK-dominant sample but not yet universal applicability.
Sources:
2026-02-27 - DISCOVER-ME publishes consortium design paper detailing multi-omics stratification approach
A formal consortium paper describing the DISCOVER-ME project appeared in early 2026, providing methodological detail beyond the 2024 funding announcement. The paper describes how 21 international partners will integrate genomics, transcriptomics, and microbiome data across harmonized biobanks to identify molecular patient clusters. The explicit methodological challenge named is pre-stratifying participants by disease severity and PEM status to prevent heterogeneity from washing out subgroup signals. The paper frames stratification as the prerequisite for making ME/CFS trials efficient: without defined subgroups, a treatment effective in one patient cluster will appear to fail in a heterogeneous population. As a design paper, it does not report biological findings, but it represents the field’s sharpest statement of what the next infrastructure investment is trying to solve.
Sources:
2026-03-03 - Hospital employee cohort finds 3.2% ME/CFS incidence after COVID-19, with EBV reactivation and autoantibodies
A prospective cohort of 221 hospital employees who tested positive for SARS-CoV-2 between 2020 and 2021 was followed to assess the rate of ME/CFS development. Among those with persistent fatigue, 11.8 percent of the total cohort qualified, and formal ME/CFS criteria (Canadian Consensus Criteria) were met by 3.2 percent. Laboratory findings showed possible Epstein-Barr virus reactivation in over 86 percent of fatigue cases and elevated anti-GPCR autoantibodies in 66.6 percent of participants assessed. The study’s occupational health design gives it a defined source cohort, which avoids the referral bias typical of clinic-based incidence estimates, but the final assessed group was small and drawn from a single hospital system. The 3.2 percent ME/CFS incidence figure is best understood as a lower-bound estimate in a healthcare worker population with access to diagnostic evaluation; true population-level rates may differ.
Sources:
2026-03-06 - INIM seminar reviews validated outcome measures for ME/CFS trials
In an invited presentation for the Nova Southeastern University Institute for Neuro-Immune Medicine (INIM) 2026 Research Seminar Series, Dr. Leonard A. Jason reviewed methodological standards for outcome measures and symptom assessment in ME/CFS research. The seminar emphasized the critical necessity of psychometrically validated instruments, such as the DePaul Symptom Questionnaire, to distinguish core features like post-exertional malaise and cognitive impairment from nonspecific fatigue. Jason outlined how unvalidated symptom checklists introduce substantial measurement error into clinical trials and observational cohorts, obscuring subgroup differences and treatment signals. As an expert seminar and conceptual review rather than a new empirical dataset, the presentation provides methodological trial-infrastructure guidance rather than testing a novel intervention. The presentation is accessible as a recorded video via Nova Southeastern University’s SharkMedia repository, though timestamped transcripts are not formally indexed.
Sources:
2026-03-17 - Large multi-country study confirms bimodal ME/CFS onset with distinct severity profiles by age group
A study analysing survey responses from more than 9,000 ME/CFS patients across 10 European countries, validated against a separate large UK dataset, found a clear bimodal age-at-onset distribution with an early peak at age 16 and a later peak at age 36. Early-onset cases were twice as likely to result in severe or very severe disability compared to later-onset cases, were more strongly associated with infectious triggers—particularly glandular fever—and showed a higher prevalence of first-degree relatives with the same condition, suggesting a stronger genetic predisposition component in adolescent-onset disease. The consistency of the bimodal pattern across multiple countries and datasets strengthens confidence in the finding despite the reliance on self-reported onset ages. Clinically, the implication is that adolescent-onset ME/CFS may represent a distinct phenotype requiring different research and clinical attention than adult-onset cases, and that genetic studies should consider whether early- and late-onset cases have different heritability architectures.
Sources:
2026-03-17 - German pediatric cohort study finds post-COVID symptom persistence correlates with acute infection severity
The German CoCo-Fakt study analyzed real-world surveillance data from two health departments (Cologne and Augsburg) in 731 children aged 15 and under with PCR-confirmed SARS-CoV-2 infection. The study observed a stepwise increase in the prevalence of persistent (lasting over 4 weeks) symptoms corresponding directly to the severity of the acute infection, ranging from 0% in asymptomatic cases up to 50% in children who experienced severe acute illness. This provides objective, real-world evidence that pediatric populations suffer from persistent post-COVID symptoms and suggests that the severity of the initial infection is a major clinical predictor of ongoing morbidity. However, the study relies on health department registries with potential underreporting, and it lacks clinical examination or formal ME/CFS diagnostic validation. Additionally, tracking symptoms only past 4 weeks may capture transient post-viral recovery rather than a chronic, long-term post-COVID syndrome.
Sources:
2026-03-25 - Charité 3rd International Conference expert perspectives paper maps consensus across mechanisms, care, and trials
A multi-author report synthesizing the 3rd International Conference of the Charité Fatigue Center, held in May 2025, was published in Autoimmunity Reviews in March 2026. The paper brought together dozens of leading international ME/CFS and post-COVID researchers to consolidate current consensus across pathophysiology, diagnostic biomarkers, clinical care models, and therapeutic trial directions. Key mechanistic consensus points included a model of sarcolemmal depolarization and Na+/K+-ATPase dysfunction in skeletal muscle and significant microvascular impairment in retinal venular function. From a clinical characterization standpoint, the paper is significant for what it names as missing: universally validated diagnostic biomarkers and standardized clinical care guidelines are identified as critical gaps requiring urgent international collaboration. Preliminary trial data from hyperbaric oxygen, immunoadsorption, and daratumumab were presented but not yet conclusive, underlining that research infrastructure consensus has moved faster than treatment evidence.
Sources:
2026-04-03 - Mayo Clinic algorithm raises diagnostic concordance from 55% to 77% in primary care referrals
A retrospective study at the Mayo Clinic evaluated the effect of introducing a point-of-care clinical decision support tool—the AskMayoExpert ME/CFS algorithm—on the accuracy of primary care referrals. Before the tool’s introduction, 55.3 percent of referrals matched the specialist’s final diagnosis; after introduction, concordance rose to 76.9 percent, with referrals 1.39 times more likely to result in a confirmed specialist diagnosis. Over 580 providers accessed the tool during the study period. The result is practically important because diagnostic delays in ME/CFS are driven substantially by insufficient clinical familiarity, and algorithmic decision support provides a scalable way to close the knowledge gap without requiring specialist training for every primary care clinician. The study is limited to a single large healthcare system and does not measure how the improved referral accuracy affected patient outcomes or time to diagnosis.
Sources:
2026-04-29 - Mayo Clinic chart review documents widespread underuse of core ME/CFS pharmacotherapy before specialist contact
A retrospective chart review of 571 adult ME/CFS patients referred to a Mayo Clinic specialty clinic between 2018 and 2022 found that while 68.3 percent had tried at least one medication before their first specialist appointment, most were for secondary symptoms like pain or anxiety. Medications specifically targeting core ME/CFS features—fatigue, brain fog, and orthostatic intolerance—were rarely prescribed at the primary care level; low-dose naltrexone, for example, appeared in very few pre-referral medication lists. More than 72 percent of patients relied on supplements in the absence of targeted pharmacological guidance. The study quantifies what clinical guidelines have described qualitatively: a systematic disconnect between specialist-level care and general practice, where clinicians manage mood and pain but leave the physiological core of the illness unaddressed. The authors argue that education and standardized treatment guides could partially close this gap without waiting for approved disease-modifying therapies.
Sources:
2026-05-07 - German CFS_CARE study finds no physical function difference for specialized inpatient rehabilitation
In a presentation at the Internationale ME/CFS-Konferenz 2026, preliminary results from the German “CFS_CARE” prospective study (funded by the G-BA Innovationsfonds) were shared. The study compared 12-month outcomes for ME/CFS patients who received specialized interdisciplinary outpatient care and a customized five-week inpatient rehabilitation program against a control group managing symptoms through standard primary care. The analysis showed no statistically significant differences between the two groups in physical function (measured via SF-36) or secondary outcomes after 12 months. This trial suggests that standard inpatient rehabilitation models—even when customized—are not effective at improving physical function in ME/CFS patients compared to routine GP care, highlighting the need for caution to avoid triggering post-exertional malaise. However, these findings are preliminary, conference-reported results that have not yet undergone peer review or been published with full data tables. The lack of benefit could stem from cohort heterogeneity or the rehabilitation design failing to sufficiently prevent exertional triggers.
Sources:
2026-05-07 - Day 1 of International ME/CFS Conference 2026 in Berlin surfaces genetics, neuroimaging, and metabolic convergence
A live social-media thread summarising the first day of the International ME/CFS Conference in Berlin covered 19 presentations from global researchers spanning genetics, neuroimaging, immunology, and metabolic dysfunction. Highlights included neural tissue enrichment of DecodeME genetic signals, distinct autoimmune endotypes from immune profiling, neuroinflammation evidenced by TSPO-PET imaging and white matter MRI, impaired brain energy metabolism measured by phosphorus MRS, and distinct lactate recovery trajectories after exertion in ME/CFS and post-infectious cohorts. The conference-level context matters for clinical characterization because it shows where the field’s subtyping efforts are converging: researchers from multiple independent groups are pointing to similar biological disruptions using different measurement modalities, which strengthens the case for pathological consistency even without yet having validated biomarkers. These are preliminary data from ongoing projects and have not yet completed full peer review.
Sources:
2026-05-10 - Full Berlin 2026 conference overview reports null trial results alongside new genetic and imaging findings
A more complete summary of both days of the 4th International ME/CFS Conference in Berlin, published by ME/CFS Science, reported on findings from more than 50 international experts. The genetic analysis from DecodeME found that ME/CFS heritability is exclusively enriched in brain tissues—specifically a rare striatal cell type called eccentric medium spiny neurons. On the clinical trial side, a 160-patient randomised controlled trial of low-dose naltrexone, a sham-controlled immunoadsorption trial from Charité, and a methylprednisolone trial all failed to meet their primary efficacy endpoints, while a 10-patient daratumumab pilot reported clinical response in 6 patients alongside autoantibody profile changes. Whole-body PET scans showed elevated muscle and bone marrow metabolic activity in patients. For clinical characterization, the null trial results are as informative as the positive signals: they indicate that broad, unstratified treatment in heterogeneous cohorts is unlikely to produce detectable effects, reinforcing the field’s shift toward requiring patient subtyping before running larger trials.
Sources:
2026-05-11 - Sequence ME & Long Covid secures £4.75 million for long-read whole-genome sequencing of 18,000 patients
Action for ME announced £4.75 million in UK government funding, primarily from the Office for Life Sciences, for Sequence ME & Long Covid, a project built on the DecodeME cohort infrastructure. The project plans to sequence the entire genomes of 9,000 people with ME/CFS and 9,000 people with Long Covid using Oxford Nanopore Technologies’ long-read sequencing, which can detect large-scale structural genomic variations and complex gene combinations that standard short-read methods miss. The initial phase will use the 6,000 existing DNA samples from DecodeME participants, with Long Covid recruitment to follow. Full funding for all 18,000 participants is still being sought. No genomic findings are available from this announcement stage. The project is significant for clinical characterization because structural genomic variants can explain conditions that GWAS-level single-nucleotide variation analysis misses, and the scale is large enough to support rare variant discovery in a patient population historically too small for genome-wide association work.
Sources:
2026-05-12 - NIH-led ethics paper establishes framework for proceeding with Long COVID disease-modifying trials
A multidisciplinary paper from the NIH Department of Bioethics and collaborating institutions, published in eClinicalMedicine, argued that transitioning Long COVID research from observational studies to clinical trials of disease-modifying treatments is an ethical necessity, not a premature step. The authors, including clinician-scientists and individuals with lived Long COVID experience, identified immunomodulatory, neurological, and antiviral drug categories as viable near-term trial targets and proposed adaptive platform trial designs as the primary tool for managing scientific uncertainty. The argument is that ongoing patient burden makes waiting for a complete mechanistic understanding of the disease ethically untenable, and that rigorous trial design can manage risks even without validated biomarkers. For clinical characterization, the paper is relevant because it signals that the international infrastructure consensus has moved to a point where large trials are being designed—and that the design standards proposed (including fair participant selection and stratified monitoring) will shape how trial cohorts are defined and enrolled going forward.
Sources:
2026-05-18 - NIH-led consensus framework establishes rigorous study design standards for infection-associated chronic illnesses
An expert consensus paper published in Brain by researchers across leading US institutions and Uppsala University’s ME/CFS Collaborative Research Centre reviewed recurring methodological failures in post-treatment Lyme disease, Long COVID, and ME/CFS research and proposed a framework for more rigorous and reproducible studies. The core requirements include precise participant classification (requiring microbiologic evidence of initial infection where feasible), use of highly defined control populations that include fully recovered individuals from the same infection, and standardised biospecimen collection protocols. The paper explicitly recognises ME/CFS as a distinct, disabling biological illness and argues that the methodological path forward mirrors what allowed multiple sclerosis research to produce reliable biomarkers and therapies. The framework does not introduce new primary findings about ME/CFS biology but sets a bar for future cohort design that, if adopted, would substantially reduce the participant misclassification and protocol heterogeneity that have made ME/CFS studies difficult to aggregate or replicate.
Sources:
2026-05-22 - Mechanistic review argues ME/CFS pathology is state-dependent and calls for challenge-based study designs
A review in the Journal of Translational Medicine by Watton and Prusty argued that ME/CFS must be understood as a disorder of impaired adaptive capacity in which biological abnormalities are revealed under physiological stress rather than at rest—explaining why routine resting laboratory values often appear normal. The paper linked persistent immune dysregulation, metabolic reprogramming, endothelial dysfunction, abnormal coagulation, and extracellular vesicle signalling into a unified post-infectious disease framework, and compiled a chart of candidate therapeutic interventions with reported clinical signals. For clinical characterization, the key methodological implication is that studies measuring biomarkers only at rest will consistently underestimate the pathological signal; the paper provides scientific grounding for challenge-based protocols and dynamic diagnostic testing. It remains a conceptual review without new primary data, but it synthesises the current mechanistic literature in a way that directly informs how future characterization cohorts should be designed.
Sources:
2026-05-19 - Patient-led platforms reframed as research infrastructure for complex chronic illness
A commentary in Oxford Open Immunology used the Visible platform as a case study for patient-led research infrastructure in ME/CFS, Long COVID, and related complex chronic illnesses. The authors argue that tools patients already use for pacing, symptom tracking, heart rate, and heart-rate variability can lower the burden of participation and collect longitudinal home-based data from people who may be too ill for clinic-based studies. That matters for clinical characterization because standard cohorts often miss the most severely affected and those with limited access to specialist centers. The model also carries limits: the paper is a commentary rather than comparative empirical evidence, and the authors include employees or scientific advisers of the platform being discussed. Its strongest role is infrastructure design, not proof that any digital platform has solved cohort bias.
Sources:
2026-05-28 - German protocol will compare Long/Post-COVID incidence and sequelae in people with and without diabetes
The longcovid-diab protocol describes a non-interventional longitudinal study using German statutory health-insurance data covering roughly 74 million insured people. The study will compare Long/Post-COVID incidence, risk factors, mortality, hospitalization, and cardiovascular or diabetic complications in people with and without diabetes, using billing codes that include Long/Post-COVID and post-COVID ME/CFS. Its value is scale: administrative data can show population-level trends and sequelae that smaller specialty cohorts cannot. The limitation is also administrative-data dependence, because coding variation, underdiagnosis, and inconsistent use of ME/CFS-related codes can distort incidence estimates. No outcome results are available yet.
Sources:
2026-06-05 - Korean PASC clustering identifies fatigue/PEM-dominant and high-multisystem profiles
A PLOS ONE latent-profile analysis of 629 Korean adults with PASC identified four symptom profiles: low-symptom, moderate multisystem, fatigue/PEM-dominant, and high multisystem burden. Fatigue and post-exertional malaise were the most prevalent and severe symptoms across the sample, and quality of life declined stepwise with symptom burden. The fatigue/PEM-dominant class is clinically important because it resembles the ME/CFS-centered phenotype seen in other post-infectious cohorts. The study also shows that regional cohorts can differ from Western reports, since a respiratory-dominant class was not prominent here. Interpretation is limited by cross-sectional design and online recruitment through Long COVID communities.
Sources:
2026-06-05 - Racialized Canadian Long COVID cohort highlights syndemic burden and ME/CFS-like PEM
A cross-sectional study of 51 racialized Canadian adults with Long COVID and pre-existing mental health challenges found clinically relevant fatigue, notable PEM, cognitive difficulties, and moderate impairment in work, social, and daily activities. The authors frame the cohort as a syndemic population, where structural inequities and pre-existing mental-health vulnerability compound Long COVID burden rather than acting as simple background variables. This is useful because it makes clinical characterization more socially realistic: symptom burden, work participation, and access to support are shaped by both biology and lived context. The study is exploratory, small, and recruited through community organizations, so it cannot define population prevalence or causal pathways. It does, however, identify a subgroup that standard biomedical cohorts can easily under-sample.
Sources:
2026-06-05 - Youth activity and participation scales validated for post-acute infection, vaccination syndromes, and ME/CFS
Researchers at the Munich Chronic Fatigue Center validated brief activity and participation questionnaires for children, adolescents, and young adults with post-acute infection or vaccination syndromes and/or ME/CFS. In 91 patients aged 10-25 years, the MCFC Activity Scale and Participation Scale correlated with the Bell Score, fatigue, PEM, and physical quality-of-life measures, and showed moderate ability to discriminate ME/CFS from related post-acute syndromes. The practical value is that pediatric and young-adult cohorts need instruments that capture school, independence, social participation, and PEM risk, not just adult work capacity. The single tertiary-center sample and modest cohort size mean the tools need broader validation. Still, they help translate clinical severity into domains families and clinicians can act on.
Sources:
2026-06-08 - Multimodal ME/CFS subgrouping protocol combines immune, autonomic, neuroinflammatory, gut, and stress-response measures
A KU Leuven and Hasselt University protocol describes a cross-sectional and longitudinal study enrolling 115 ME/CFS patients and 55 controls to identify neuropsychophysiological subgroups. The baseline design combines systemic cytokines, heart-rate variability, MRS and PET neuroinflammation measures, gut microbiota, short-chain fatty acids, stress-response testing, cognitive and physical fatigability, and 7-day experience sampling. The longitudinal phase follows patients through routine clinical CBT rehabilitation, which makes treatment-response interpretation open-label and expectation-sensitive. The study is valuable as a characterization design because it explicitly tests whether multimodal signals can define subgroups instead of treating ME/CFS as one homogeneous cohort. No outcome data are available yet.
Sources:
2026-06-08 - Sixteen-year follow-up of women with ME/CFS shows long-term comorbidity and worsening fatigue burden
A Serbian longitudinal study followed 20 women with ME/CFS for 16 years after an original cohort of 40, finding that 85% developed at least one significant new somatic or psychiatric diagnosis and that fatigue impact worsened on follow-up measures. Reported new diagnoses included depression, rheumatoid arthritis, hypertension, cancer, asthma, premature myocardial infarction, and infertility. The study is clinically important because it argues against assuming ME/CFS is generally benign or self-limiting over long time horizons. Its small female-only sample, 50% loss to follow-up, and lack of a matched control group mean the comorbidity rates should not be read as population incidence estimates. The durable signal is that long-term follow-up and comorbidity surveillance matter.
Sources:
2026-06-09 - AAN abstract links Long COVID symptoms with joint hypermobility in a small specialty-clinic cohort
An AAN conference abstract reported a retrospective cohort of 20 Long COVID patients seen in post-COVID and hypermobility clinics, all with Beighton scores of at least 5. Fatigue, brain fog, and PEM were common, and younger patients were more likely to show more severe hypermobility. The abstract is relevant because connective-tissue traits and dysautonomia often cluster clinically with ME/CFS-like post-viral illness. It is not strong evidence of prevalence or causality: the cohort is tiny, highly selected, and available only as a conference abstract. Its best use is as a prompt for better-designed studies on hypermobility, orthostatic intolerance, and post-infectious symptom persistence.
Sources:
2026-06-13 - Connective-tissue hypothesis paper proposes links between laxity, mast cells, hypoxia, and ME/CFS symptoms
Klaus Wirth published a hypothesis preprint arguing that connective-tissue laxity, mast-cell activation, hypoxia signaling, capillary basement-membrane changes, and skeletal-muscle dysfunction may reinforce one another in ME/CFS. The clinical characterization value is that it offers a framework for why hypermobility, orthostatic intolerance, craniocervical complaints, and exertional intolerance can co-occur in some patients. It does not present new patient data and should not be treated as proof that connective-tissue pathology causes ME/CFS. The main implication is cohort design: studies may need to record hypermobility, cervical instability symptoms, and mast-cell features when characterizing subgroups.
Sources:
2026-06-15 - Qualitative study defines ME/CFS self-management support needs for patients and next of kin
A Norwegian qualitative study interviewed 12 people with ME/CFS and 4 next of kin about self-management support. Participants described a need for individualized timing, flexible digital or hybrid formats, continuity, validation, peer support, pacing tools, and family-inclusive guidance. The study also found that existing support is often poorly aligned with cognitive and physical limitations, and that patients receive inconsistent activity-management advice. This belongs in clinical characterization because support design determines whether evidence-based concepts like pacing are actually usable for patients. The sample is small and context-specific, so it should guide care-model design rather than define universal preferences.
Sources:
2026-06-18 - German neuroscientific assessment statement warns many proposed PCS/ME/CFS tests lack individual diagnostic specificity
The German Society for Neuroscientific Assessment published a consensus statement on diagnostic methods for Post-/Long-COVID syndromes and overlap with ME/CFS. It concludes that several commonly cited tests, including GPCR autoantibodies, heart-rate variability, commercial stool tests, surface electromyography, handgrip dynamometry, and routine structural or functional brain imaging, do not yet have enough specificity to prove PCS or ME/CFS at the individual level. This is an important counterweight to the growth of biomarker enthusiasm: many tools can be useful in research cohorts without being ready for forensic or clinical proof in a single patient. The statement is conservative and assessment-focused, so it should not be read as denying biological abnormalities. It clarifies where clinical documentation still depends on careful history, PEM assessment, functional impact, and validated exclusion workups.
Sources:
2026-06-21 - German PEDNET-LC network establishes nationwide clinical care and registry infrastructure for pediatric syndromes
In a presentation at the Internationale ME/CFS-Konferenz 2026, the structure and objectives of the new PEDNET-LC network were outlined. Funded with approximately €41-45 million by the German Federal Ministry of Health (BMG), this initiative connects 20 specialized care centers, pain clinics, rehabilitation facilities, and research institutes across Germany. The network aims to standardize pediatric diagnostic tools, establish clinical care pathways, and build a centralized registry to collect longitudinal clinical and biological data for children and adolescents suffering from Long COVID, post-vaccination syndromes, and ME/CFS. This builds substantial national clinical and research infrastructure specifically tailored to pediatric cohorts, a population historically facing severe care shortages, and creates a structured dataset to support future clinical trials. As a conference presentation, it focused on infrastructure and registry design rather than final clinical outcomes or mechanistic discoveries. Furthermore, the registry and care pathways are currently restricted to the German healthcare system.
Sources:
2026-06-22 - Jordan Delphi study adapts home-based pulmonary rehabilitation for Long COVID with PEM safeguards
A modified e-Delphi study with 15 multidisciplinary experts developed a culturally adapted home-based pulmonary rehabilitation program for Long COVID in Jordan. The final consensus emphasized low-technology delivery, phone-based supervision, Borg RPE monitoring, symptom-contingent progression, pacing, energy conservation, and mandatory PEM screening. This matters because rehabilitation designs that ignore PEM can cause harm, while resource-limited settings need feasible models that do not rely on intensive specialist access. The study is consensus-based and has not yet shown clinical outcomes. It is best treated as care-model design, not proof that rehabilitation improves PEM-defined illness.
Sources:
2026-06-25 - Cohen Center updates detail pilot trial results of microtesla magnetic therapy and antiviral combination protocol
At the Internationale ME/CFS-Konferenz 2026, clinical trial updates from the Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai were presented. The updates included positive safety and feasibility results from a completed 30-participant, triple-blind, randomized controlled trial of Farion’s “Mighty” home-use microtesla magnetic therapy (MMT) device, showing exploratory cognitive speed benefits. Additionally, case series data for 26 patients treated with the “Prigen protocol” (combining valacyclovir, celecoxib, and a 15-day course of Paxlovid) showed durable symptomatic improvements on the Patient Global Impression of Change up to two years post-treatment. These preliminary signals offer feasibility data for home-based magnetic therapy and long-term antiviral/anti-inflammatory combination therapies, supporting planned larger validation trials. However, these are preliminary conference reports rather than peer-reviewed papers. The MMT trial was a very small pilot (n=30) requiring larger replication, and the Prigen protocol data are based on an open-label, non-randomized case series (n=26) subject to selection and placebo biases.
Sources:
2026-06-28 - Patient-led Long COVID clustering study shows high-burden PEM groups but warns against over-interpreting algorithmic phenotypes
The Patient-Led Research Collaborative analyzed 162 self-reported symptoms from 6,031 adults with Long COVID using three unsupervised clustering methods. All methods produced plausible groups and consistently found a high-symptom-burden subgroup enriched for severe PEM, younger age, and female sex, but agreement between algorithms was low and the symptom landscape appeared continuous rather than clearly partitioned. The result is useful because it validates PEM-heavy Long COVID as a recurring clinical pattern while warning that symptom clusters are partly method-dependent. Biomarker integration will be needed before these groupings can become stable endotypes for trials. Online self-report recruitment and lack of objective measures remain the main limitations.
Sources:
2026-06-28 - Austrian PAIS/PEM guidance defines PEM and POTS assessment for primary care
The Tiroler Gesellschaft für Allgemeinmedizin and the PAIS Quality Circle of the Tyrolean Medical Chamber published clinical guidance on PEM in post-acute infection syndromes. The document defines PEM as delayed, disproportionate symptom worsening after physical or mental exertion, emphasizes that PEM is not deconditioning and is not reversed by training, and recommends tools such as DSQ-PEM and FUNCAP55 for screening. It also outlines POTS criteria and a staged laboratory-workup framework based on illness duration. The guidance is expert-consensus and living-document material rather than trial evidence, but it is useful for primary care because it translates PEM and orthostatic assessment into practical steps. Its central safety message is that active or graded rehabilitation is inappropriate when PEM is present.
Sources:
2026-06-28 - CBT component meta-analysis requires cautious interpretation for PEM-defined ME/CFS
A component network meta-analysis reviewed cognitive behavioral therapy components and delivery formats for chronic fatigue syndrome/ME/CFS. Because much of the CBT literature uses older or broader fatigue criteria, subjective outcomes, and trial designs that predate current PEM-centered safety standards, the findings should not be generalized as evidence that CBT is curative or disease-modifying for PEM-defined ME/CFS. Its main relevance here is methodological: it shows how strongly conclusions can depend on case definition, outcome selection, and whether harms or delayed post-exertional worsening are captured. Any psychological or behavioral support studied in ME/CFS needs to be distinguished from claims that symptoms are maintained by beliefs or that fixed activity increases are safe. This source should therefore inform trial-design caution rather than patient-facing treatment promises.
Sources:
2026-06-28 - Qualitative recovery narratives remain self-reported and should not be treated as proof of cure
A qualitative study on women who described recovery from ME/CFS outside formal clinical settings is relevant to lived-experience research, but it must be framed narrowly. The study can describe perceived pathways, social supports, self-management strategies, and how people make sense of improvement, but it does not objectively verify recovery with physiological testing, diagnostic re-evaluation, or long-term relapse monitoring. That distinction matters because ME/CFS fluctuates and because recovery narratives can be misused to imply that most patients can recover through behavioral change alone. The useful clinical characterization point is that patients’ accounts of improvement deserve study, while claims about cure or general recovery expectations require much stronger evidence.
Sources:
2026-06-28 - Mold-exposure funding announcement adds one environmental-risk research thread, but no results yet
Nova Southeastern University announced NIH funding to study possible links between mold exposure and ME/CFS. The planned study will collect biological samples from more than 200 participants, measure mycotoxin exposure, and test whether specific exposures map onto biological changes associated with ME/CFS. This is relevant because environmental exposures are often discussed by patients but are rarely studied in adequately characterized cohorts. At this stage it is a funding and project announcement only, without enrollment results, exposure-response findings, or validated mechanisms. It should be tracked as research infrastructure rather than evidence that mold exposure is a proven ME/CFS cause.
Sources:
2026-06-30 - Sex- and menopause-related differences in symptom architecture highlight distinct hormonal influences
A sex-stratified structural equation modeling and factor analysis preprint involving 748 adults (608 women, 137 men) with ME/CFS examined immune and gastrointestinal symptom architectures. In women, immune symptoms (flu-like symptoms and infection susceptibility) and gut symptoms (gastrointestinal complaints and food intolerances) formed two distinct, separable clusters, whereas in men, all immune and gut symptoms loaded onto a single integrated factor. Furthermore, premenopausal women reported significantly more frequent flu-like symptoms than postmenopausal women, while gastrointestinal symptoms remained stable across menopausal status. This suggests that ME/CFS manifests with different biological and symptom structures between sexes, and that female hormones may dynamically modulate immune pathways, highlighting the necessity of sex-stratified trial designs. As a preprint, these findings remain preliminary and have not yet undergone peer review. Additionally, the study relies on self-reported dichotomous symptom coding and features a female-skewed sample that reduces comparative statistical power for men.
Sources:
2026-06-30 - Pan-European DISCOVER-ME consortium secures €7.5M to build biomarker-guided clinical networks
The European ME Research Group (EMERG) consortium secured a €7.5 million Horizon Europe grant to launch the “DISCOVER-ME” project, led by Prof. Eva Untersmayr-Elsenhuber and Prof. Simon Carding. Connecting over 20 institutions across Europe and Canada, the project aims to establish standardized clinical and laboratory protocols across multiple European biobanks. The ultimate goal is to validate biomarkers across genetic, immune, metabolic, neuroendocrine, and vascular domains while embedding patient-led organizations to inform stratification and future trial designs. This builds large-scale, standardized research infrastructure across European biobanks, establishing a unified foundation for biomarker validation and patient stratification in future clinical trials. As a research infrastructure initiative, it does not directly test new treatments or provide immediate diagnostic tools for clinical use. The timeline for translating these standardized biobank findings into clinical trials and approved diagnostics will span several years.
Sources:
2026-07-01 - Post-COVID study separates trait fatigue, state fatigue, and task-induced fatigability
A peer-reviewed cross-sectional study published in Social Science & Medicine evaluated how fatigue operates across cognitive, motor, and emotional domains in adults with Post-COVID Condition. The authors empirically distinguished baseline trait fatigue from momentary state fatigue and task-induced performance fatigability, demonstrating significant impairments across all three functional spheres. The findings validate patient accounts that post-viral exhaustion extends beyond general physical fatigue into distinct, measurable cognitive and emotional processing fatigability. A central limitation is that the study evaluated a broad Post-COVID cohort without applying formal ME/CFS case definitions or conducting 2-day CPET post-exertional malaise characterization. Furthermore, the requirement for active in-person cognitive and motor testing batteries systematically excluded severe and bedbound individuals, and the cross-sectional design precludes establishing longitudinal trajectories.
Sources:
2026-07-01 - DecodeME symptom analysis of 19,019 UK participants identifies two main severity subgroups linked to onset type
A preprint using data from 19,019 UK participants in the DecodeME cohort applied k-modes cluster analysis to patient symptoms. The analysis identified two primary patient subgroups: a High Symptom Burden Cluster (HSBC) comprising 57% of participants, characterized by greater illness severity and comorbidities, and a Lower Symptom Burden Cluster (LSBC) comprising 43%. Participants who reported an infectious or unknown illness onset had significantly higher adjusted odds of belonging to the HSBC compared to those with a non-infectious onset. A companion genome-wide association study (GWAS) for cluster membership failed to identify any genome-wide significant genetic variants associated with either subgroup. This indicates that ME/CFS symptom severity can be stratified into distinct subgroups, showing a strong link between infectious triggers and long-term symptom severity. As a preprint, these findings remain preliminary and have not yet completed peer-review. Furthermore, the negative GWAS findings suggest that the genetic architecture of severity is either highly complex or largely non-genetic.
Sources:
2026-07-06 - Multimodal study protocol outlines biological subgrouping framework for ME/CFS
A published study protocol for a multimodal mechanistic trial led by researchers at KU Leuven and Hasselt University details a prospective cross-sectional and longitudinal study design enrolling 115 ME/CFS patients and 55 healthy controls. The protocol combines functional magnetic resonance imaging (fMRI), autonomic nervous system testing, 18F-FEPPA PET neuroinflammation imaging, gut microbiome sequencing, short-chain fatty acid measurements, and 7-day ecological momentary assessment (EMA). By integrating systemic immune, neuroinflammatory, autonomic, and microflora parameters, the study aims to replace homogeneous cohort assumptions with objective neuropsychophysiological endotypes. Clinically, this multimodal approach addresses a core research barrier by identifying whether distinct biological subgroups predict treatment response to pacing and rehabilitation interventions. A key limitation is that as a study protocol paper, it describes experimental design and methodology prior to empirical data collection and subgroup validation.
Sources:
2026-07-07 - Survey and EMR analysis reveals gaps in Long COVID diagnostic coding
A cross-sectional survey (n = 205) and electronic medical record (EMR) sub-analysis (n = 100) investigated the relationship between patient-reported Long COVID symptom interference and official clinical diagnostic coding. In the survey cohort, 41% of participants reported high symptom interference with daily life activities, which significantly correlated with older age, female sex, obesity, poorer general, physical, and mental health metrics, and the presence of a U09.9 diagnosis code. However, among those reporting high symptom interference, only 64% (25 of 39) in the EMR sub-analysis actually had a corresponding Long COVID diagnostic code documented. While the study found no evidence of demographic biases in receiving a diagnosis among patients experiencing high symptom interference, it highlights a notable gap between patient-reported severity and clinical coding. Limitations include the cross-sectional design, reliance on self-reported survey data susceptible to recall bias, and a small EMR sub-analysis sample.
Sources:
2026-07-09 - Pre-infection exercise shows no association with persistent post-COVID symptoms in 5,413 adults
A peer-reviewed epidemiological study published in Sports by Schmidt et al. analyzed 5,413 adults from the German CoCo-Fakt surveillance registry to investigate whether pre-infection physical activity influenced persistent post-COVID symptoms. Persistent symptoms lasting beyond 12 weeks were reported by 10.4% (n=561) of the broad post-COVID cohort. While initial multivariable models suggested a weak correlation between higher pre-infection exercise intensity and persistent symptoms, this association became non-significant after Bonferroni-Holm correction for multiple testing. The study found no evidence that pre-infection activity predicted persistent symptoms and argues against the assumption that affected people were simply unfit beforehand. However, a null result based on retrospective self-report is not proof that activity has no effect. Other limitations include a broad PASC scope lacking ME/CFS criteria or objective PEM characterization and online survey administration that likely underrepresents severe and bedbound patients.
Sources:
2026-07-10 - National registry and healthcare surveys in the US, New Zealand, and Australia highlight socioeconomic burden and diagnostic gaps
Three large-scale studies profiled the socio-economic impact and health services landscape of ME/CFS and Long COVID. In New Zealand, a nationwide Integrated Data Infrastructure (IDI) study of 1,902 benefit recipients with ME/CFS found extremely low employment rates (18.3% vs. 83.8% controls), high polypharmacy (32.8%), and a low rate of disability support service usage (1.6% vs. 7.2% other benefit recipients) indicating major structural barriers to care. In the US, an analysis of the 2021-2023 National Health Interview Survey (NHIS) representing 86,655 adults estimated that 1.5% have received an ME/CFS diagnosis, and found that among the 20.7% who reported past (resolved) ME/CFS, 40-50% still experienced active symptoms and functional impairment comparable to those with active disease. Finally, an Australian review of Long COVID service delivery documented severe fragmentation following public clinic closures, forcing patients into private fee-for-service clinics, and highlighted “statistical invisibility” due to a lack of active diagnostic codes as a major barrier to surveillance and service capacity planning. Collectively, these registry and guideline evaluations show that standard administrative databases significantly underestimate the true illness burden, and that patients face severe, systemic barriers to obtaining specialized care, benefits, and accurate diagnostic tracking. However, these studies rely heavily on administrative diagnostic codes, which are prone to misclassification, or self-reported survey data without clinical validation. Furthermore, the services mapped are highly system-specific to New Zealand, the US, and Australia.
Sources:
- New Zealand IDI study: Wheeler et al. 2026, Journal of Health Psychology
- US NHIS survey: CDC reports 2026
- Australian service review: Hall et al. 2026, Medical Journal of Australia
2026-07-10 - Large cohort studies in Germany, China, and the UK validate distinct symptom clusters and comorbidity burden
Three studies validated symptom clustering and burden using statistical modeling. In Germany, a factor analysis and structural equation modeling (SEM) study of 748 adult patients in the APAV-ME/CFS study confirmed that symptoms group into distinct, functional biological systems, demonstrating an excellent model fit for a “Brain” factor, a two-factor “Gut-Immune” structure, and a higher-order “Autonomic” symptom complex. In China, a cross-sectional case-control study of 1,821 participants (956 patients, 865 controls) at Shanghai Shuguang Hospital reported that patients experienced twice the fatigue severity compared to controls across all MFI-20 domains, and identified comorbid insomnia and GI discomfort as major contributors to poor health outcomes. In the UK, a preprint study of 1,028 adult patients using the new “Index of ME Symptoms” (TIMES) questionnaire applied Rasch analysis to create a 0–100 interval scale, reporting a severe cumulative multi-system symptom burden (mean score 57.2/100) with cognitive symptoms ranked as the most troublesome and women experiencing higher symptom burden than men. These studies validate that patient-reported symptoms are not random or isolated but group into coherent biological clusters, providing a standardized, psychometrically validated method (TIMES) to measure cumulative multi-system burden. However, these symptom clusters are modeled based on subjective questionnaire responses rather than direct biological measurements, and the TIMES study remains a preliminary preprint. Additionally, the cohorts are geographically restricted to Germany, China, and the UK.
Sources:
- APAV study: Alisch et al. 2026, Journal of Translational Medicine
- Shanghai Shuguang Hospital study: Wang et al. 2026, Medicine
- TIMES survey preprint: Horton et al. 2026, medRxiv
2026-07-10 - Actigraphy study links irregular light exposure patterns with worse fatigue, sleep, and metabolic markers in ME/CFS
An observational cross-sectional study using wrist-worn actigraphy monitored light exposure, activity, and wrist temperature in 100 ME/CFS patients and 56 healthy controls at home for one week. Principal component analysis revealed that a “healthy” light pattern (stable daytime light, low nocturnal light) was associated with significantly reduced fatigue, fewer sleep complaints, and milder autonomic dysfunction. In contrast, irregular or nocturnal light exposure correlated with worse clinical symptoms, lower serotonin concentrations, and elevated levels of triglycerides and vascular cell adhesion molecule-1 (VCAM-1). This identifies light exposure patterns as a potentially modifiable, non-invasive lifestyle target for stabilizing circadian rhythms and managing multi-system symptoms. However, due to the observational, cross-sectional design, causality cannot be established. Severely ill or photophobic patients may simply be unable to get daytime light exposure due to being housebound or sensitive to sensory overload.
Sources:
2026-07-13 - Australian registry study profiles health-related quality of life and case definitions in ME/CFS
An Australian registry-based study compared 2,873 ME/CFS patients against 797 non-fatigued controls between 2014 and 2026 to assess health-related quality of life (HRQoL) and clinical presentation. Within the registry cohort, patients met different case criteria, with 39.0% meeting the Fukuda definition, 30.4% meeting the Canadian Consensus Criteria (CCC), and 30.6% meeting the International Consensus Criteria (ICC). Although patients meeting the strict ICC criteria were more likely to report the poorest outcomes, HRQoL was severely and globally impaired across all ME/CFS patients compared to controls, regardless of the specific case definition met. Using K-means clustering, the researchers identified four distinct patient clusters based on symptom severity, frequency, and case criteria. The study is limited by its cross-sectional design, reliance on self-reported questionnaire data prone to recall bias, and potential selection bias from drawing participants from a specialized neuroimmunology registry.
Sources:
2026-07-17 - ME/CFS Research Foundation announces €2.4 million in funding for seven new studies
The ME/CFS Research Foundation announced €2.4 million in funding for seven new research projects under its Research Funding Programme 2026, scheduled to begin in the summer of 2026. Selected from approximately 30 submissions by an international expert jury and advisory board, the projects will focus on investigating new treatment approaches, disease mechanisms, and biomarkers. As this is a brief funding press release rather than a peer-reviewed scientific study, it does not provide clinical data, patient outcomes, or specific study methodologies, and the exact details of the individual projects are not disclosed.
Sources:
2026-07-17 - Deutsche Gesellschaft für ME/CFS publishes guidance on participatory health research standards
The Deutsche Gesellschaft für ME/CFS published a guidance document establishing principles and methodology for participatory health research (patient-led research) in ME/CFS study design and clinical trials. The framework defines standards for embedding patient representatives directly into trial co-design, primary outcome selection, protocol safety screening, and institutional ethics review. From a research infrastructure perspective, formalizing patient participation ensures that study protocols account for post-exertional malaise and severe functional impairment, preventing inappropriate exercise interventions that risk patient harm. The guidance also provides tools to optimize participant recruitment, longitudinal retention, and data validity in complex chronic illness cohorts. The document functions as an organizational policy and methodological standard rather than reporting novel biological data or clinical trial outcomes.
Sources:
2026-07-19 - Health services study identifies critical gaps in physiotherapy workforce capacity for Long COVID
A health services research study published in Respiratory Medicine evaluated physiotherapy workforce knowledge, institutional readiness, and service capacity for delivering post-COVID rehabilitation care. The assessment identified widespread gaps in physiotherapist training regarding post-exertional malaise (PEM) recognition, orthostatic intolerance screening, and physiological pacing limits. Clinically, these findings highlight a critical risk in current care delivery: without guideline-aligned education, routine exercise-based rehabilitation (such as graded exercise therapy) may be inappropriately prescribed, triggering severe post-exertional relapses in Long COVID and ME/CFS patients. The study underscores the urgent necessity of integrating post-viral exertional physiology into professional physical therapy curricula and clinical service planning. The investigation relied on workforce surveys and health service capacity metrics, and did not prospectively track clinical patient outcomes under modified pacing protocols.
Sources:
2026-07-20 - Retrospective cohort finds 48.7% circadian rhythm sleep-wake disorder comorbidity in chronic fatigue syndrome
A peer-reviewed retrospective cohort study published in Frontiers in Psychiatry investigated comorbid circadian rhythm sleep-wake disorders (CRSWDs) in 610 patients with chronic fatigue syndrome. Within the training cohort (n=427), 48.7% of patients met clinical criteria for comorbid CRSWD, with multivariable regression identifying female sex and shift work as independent risk factors. Conversely, a higher percentage of slow-wave sleep on overnight polysomnography was significantly protective against circadian disruption. The authors constructed a predictive clinical nomogram combining demographic and polysomnographic variables, but this tool remains internally validated and is not yet an established clinical screening instrument. The study is limited by its single-center retrospective design, its reliance on 1994 Fukuda criteria which do not mandate post-exertional malaise, and the logistical demands of in-lab polysomnography that systematically underrepresent severe and bedbound individuals.
Sources:
2026-07-21 - US NHIS analysis links multimorbidity to nearly half the statistical association between depression history and ME/CFS
A peer-reviewed cross-sectional analysis of 2021–2023 US National Health Interview Survey (NHIS) data published in Frontiers in Public Health evaluated the statistical links between depression history, chronic multimorbidity, and self-reported ME/CFS. While a history of depression was associated with 1.61-fold increased odds of current ME/CFS, a composite chronic disease history score comprising conditions such as arthritis, asthma, and hypertension exhibited a strong non-linear association (OR 2.49). Statistical mediation modeling revealed that cumulative multimorbid disease burden accounted for 47.2% of the total association between depression history and ME/CFS in the overall adult sample, rising to 59.2% in adults aged 50–64. The disease history score did not improve diagnostic discrimination or reclassification metrics, confirming that multimorbidity does not serve as an independent diagnostic classifier. As a cross-sectional self-reported survey lacking standardized IOM or Canadian Consensus Criteria validation and post-exertional malaise measurement, the study cannot establish whether depression or chronic comorbidities precede, accompany, or result from ME/CFS.
Sources:
2026-07-22 - Swiss observational study details care access disparities and insurance hurdles in Post-COVID Condition
An observational healthcare study published in Healthcare (Basel) evaluated Post-COVID-19 Condition (PCC) pathways within the Swiss medical system, focusing on care delivery bottlenecks, diagnostic delays, and patient burden. The study documented substantial waiting times for specialized post-COVID consultations alongside pronounced disparities in insurance reimbursement approvals for diagnostic workups and off-label symptom management. Affected individuals reported high persistent symptom severity, marked functional impairment, and widespread reduction in working capacity or job loss. Clinically, the study quantifies how structural healthcare fragmentation and administrative barriers exacerbate disease burden, demonstrating that access to multidisciplinary care remains highly unequal even in high-resource healthcare systems. A major limitation is that the survey design was subject to selection bias toward patients actively seeking specialist care or engaged with patient advocacy registries.
Sources:
2026-07-23 - Consensus framework in Clinical Infectious Diseases defines recognition and care for infection-associated chronic conditions
A major consensus policy and clinical paper published in Clinical Infectious Diseases established an overarching framework for Infection-Associated Chronic Conditions and Illnesses (IACCs), endorsed across infectious disease specialty organizations. The document provides formal guidance for recognizing, diagnosing, and coordinating multidisciplinary care for overlapping post-infectious syndromes, including ME/CFS, Long COVID, and chronic post-treatment Lyme disease. By emphasizing shared clinical features and underlying pathobiology—such as chronic immune activation, autonomic dysregulation, and neuroinflammation—the framework seeks to eliminate systemic clinical skepticism and streamline diagnostic pathways. For clinical characterization, this consensus marks a institutional shift toward integrating post-viral conditions into standard infectious disease education and healthcare delivery. As a clinical consensus and policy recommendation framework, it does not present new empirical trial data or novel biological biomarker discoveries.
Sources:
2026-07-24 - Science journalism feature highlights macroeconomic burden and healthcare deficits of ME/CFS in Germany
An investigative episode of the German science podcast series ‘Forschungsquartett’ (co-produced by Spektrum.de and detektor.fm) examined the macroeconomic impact, workforce loss, and medical care infrastructure gaps associated with ME/CFS in Germany. The report synthesized health-economic data detailing multi-billion euro indirect costs driven by long-term disability, alongside severe structural deficits in medical education, diagnostic coding, and specialized clinical care capacity. Publicly framing ME/CFS as a major socioeconomic and health-policy priority helps drive institutional momentum for clinical trial funding and healthcare system reform. However, as a secondary science journalism feature and podcast recap, the episode presents synthesized expert commentary and economic estimates rather than primary peer-reviewed scientific trial data.
Sources:
2026-07-24 - MedUni Vienna receives inaugural WE&ME Award for mechanistic ME/CFS endotype project
The Medical University of Vienna announced the receipt of the inaugural €450,000 WE&ME Award, funded by the WE&ME Foundation through the Austrian Science Fund (FWF) alpha+ Foundation, for an ME/CFS research initiative. The four-year project, titled “Mechanistic Endotypes in ME/CFS” and led by Dr. Matthias Wielscher and Prof. Kathryn Hoffmann, officially commences on September 1, 2026. The initiative aims to integrate comprehensive clinical symptom phenotyping with genetic mechanism scores derived from the large UK DecodeME cohort to identify distinct biological patient endotypes. By mapping biological subgroups, the project seeks to resolve clinical heterogeneity and lay the groundwork for targeted trial stratification and individualized therapies. As a research infrastructure and funding announcement, no empirical biological or clinical trial results are yet available, and candidate genomic subtyping models will require prospective validation.
Sources:
2026-07-25 - European Respiratory Journal publishes international clinical practice guidelines for Long COVID
An international clinical practice guideline published in The European Respiratory Journal provided evidence-graded recommendations for clinicians evaluating and treating adults with Long COVID. The guidelines outline standardized diagnostic algorithms for primary care physicians, pulmonologists, and rehabilitation specialists, covering symptom screening, exclusion workups, and multidisciplinary management strategies. The panel emphasized activity pacing and symptom-contingent management while evaluating candidate pharmacological interventions. Clinically, the guideline establishes an authoritative benchmark for routine medical practice, helping standardize post-COVID care across international healthcare settings. A critical caveat noted by the authors is that many recommended pharmacological therapies rest on low-to-moderate certainty evidence, highlighting the ongoing need for rigorous randomized controlled trials.
Sources:
2026-07-25 - Systematic scoping review maps post-COVID new-onset fibromyalgia and diagnostic overlap with ME/CFS
A systematic scoping review published in the Journal of Translational Medicine analyzed literature on new-onset fibromyalgia manifestations following non-hospitalized COVID-19. The review examined post-viral pain phenotypes, central sensitization mechanisms, small-fiber neuropathy overlap, and methodological inconsistencies across published cohorts. It highlighted substantial diagnostic ambiguity between post-COVID fibromyalgia and ME/CFS, noting that many studies fail to rigorously evaluate post-exertional malaise. Clinically, this scoping analysis emphasizes the necessity of careful differential diagnosis to ensure post-viral pain patients receive appropriate pacing guidance rather than harmful exercise prescriptions. The conclusions are limited by high heterogeneity and variable quality across included secondary studies, as well as an absence of prospective baseline data prior to viral infection.
Sources:
2026-07-25 - Peer-reviewed evaluation validates CureME participatory research and biobank infrastructure model
A peer-reviewed publication evaluated the UK ME/CFS Biobank (CureME) participatory research framework, demonstrating how patient-partnered governance, longitudinal biobanking, and open data sharing resolve systemic barriers in ME/CFS research. The study showed that integrating patient representatives into protocol design and sample collection strategies significantly improved cohort characterization, longitudinal sample retention, and data quality. Infrastructure initiatives of this caliber are essential for enabling reproducible multi-omics research and providing high-quality biospecimens for international validation studies. The paper represents a descriptive methodology and infrastructure evaluation rather than a clinical outcome study or biological biomarker discovery trial.
Sources:
2026-07-25 - Qualitative study reveals coverage gaps in patient-reported outcome measures for Long COVID
A qualitative study published in Quality of Life Research evaluated patient comprehension, cognitive validity, and item coverage across widely used patient-reported outcome measures (PROMs) in Long COVID research. Qualitative interviews with patients demonstrated that standard health questionnaires frequently fail to capture core post-viral features, specifically post-exertional symptom exacerbation, cognitive fluctuations, and post-exertional delay. Ambiguous item phrasing and inappropriate recall windows were shown to induce misinterpretation and measurement error. Psychometrically, these findings indicate that unvalidated PROMs risk underestimating treatment response or missing key clinical deterioration in clinical trials. The study focused on survey design and cognitive debriefing, without collecting physiological data or testing therapeutic interventions.
Sources:
2026-07-25 - Medical perspective paper rejects psychogenic misattribution and defines supportive care role
A peer-reviewed perspective article published in PubMed evaluated the role of psychiatry and psychotherapy in ME/CFS and Long COVID, establishing that somatic biomedical pathology is primary and firmly rejecting historical psychogenic or psychosomatic misattributions. The authors argued that mental health support must be strictly evidence-based, patient-centered, and restricted to helping individuals cope with severe chronic illness burden, rather than claiming curative potential or assuming psychological perpetuation. Clinically, this paper provides an important conceptual benchmark for protecting patients from harmful exertional therapies and diagnostic stigma while supporting legitimate psychological care for chronic illness burden. As an ethical and clinical perspective paper, it presents theoretical analysis rather than empirical clinical trial data or biological cohort measurements.
Sources:
2026-07-27 - Structural equation modeling demonstrates sex- and menopause-related variations in ME/CFS symptom architecture
A cross-sectional study of 748 adults with ME/CFS published in the Journal of Translational Medicine applied factor analysis and structural equation modeling (SEM) to assess sex- and menopause-specific latent symptom structures. The analysis revealed distinct symptom architectures between sexes: female patients presented with two partially separable symptom factors (immune vs. gastrointestinal), whereas male patients exhibited a single integrated gut-immune factor. Furthermore, premenopausal women reported significantly higher flu-like symptom frequency than postmenopausal women, while gastrointestinal symptom severity remained stable across menopausal stages. Clinically, this evidence proves that biological sex and hormonal status dynamically shape ME/CFS symptom expression, underscoring the necessity of sex-stratified design in clinical trials. A key limitation is the cross-sectional, self-reported survey design, which requires prospective longitudinal validation alongside objective endocrine and immunological biomarkers.
Sources:
2026-07-27 - Deutschlandfunk investigative audio series synthesizes research acceleration and trial pipelines in ME/CFS
Part 2 of Deutschlandfunk’s investigative science radio feature (‘Wissenschaft im Brennpunkt’) synthesized current biomedical research progress across international research groups. The broadcast detailed emerging pathophysiological models—including DecodeME genetic findings, sodium-potassium pump dysfunction, microvascular impairment, and autoantibody-mediated vascular damage—while profiling off-label trial pipelines such as daratumumab. Featuring expert commentary from leading researchers, the feature outlined key bottlenecks in European research funding and clinical trial infrastructure. While providing high-signal public science synthesis, the broadcast remains a journalistic media report rather than a peer-reviewed empirical scientific publication.
Sources:
2026-07-29 - ME/CFS Research Foundation launches 2026 research funding program
The ME/CFS Research Foundation announced the official launch of its 2026 research funding cycle, opening grant applications for targeted biomedical research projects. The program focuses on expanding private foundation funding for projects investigating disease mechanisms, objective biomarker validation, and novel therapeutic targets in ME/CFS. By funding multi-center collaborative projects in Germany and internationally, the initiative seeks to bridge financial gaps in public research infrastructure. As an official funding program press release, the document details grant availability and strategic research priorities without reporting scientific data or clinical trial results.
Sources:
2026-08-01 - Eight-country network cohort study evaluates post-acute COVID-19 autoimmune risk and EMR coding limits
A multi-country network cohort study published in BMJ Public Health analyzed electronic health record (EHR) data across eight countries (covering Europe, the US, and Korea) to quantify post-acute autoimmune and inflammatory diagnoses following COVID-19. The study evaluated relative risks for conditions including rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, and ME/CFS/POTS over a 9-month follow-up window. While providing large-scale multi-population tracking, the authors highlighted critical diagnostic coding limitations in administrative EHR databases, where ME/CFS and dysautonomia are frequently undercoded due to diagnostic delays and absent billing codes. Clinically, the study demonstrates that the lack of electronic health record code elevation in administrative databases does not rule out individual post-viral illness, underscoring the gap between clinical reality and health system coding. The study’s observational database design remains subject to misclassification and detection bias.
Sources:
2026-08-01 - Epidemiological survey of 8,840 secondary students in Shaanxi Province documents 2.06% CFS prevalence and physical impairment
A cross-sectional epidemiological study published in PubMed surveyed 8,840 secondary school students across 25 schools in Shaanxi Province, China, assessing Chronic Fatigue Syndrome (CFS) prevalence and physical health correlations. The survey identified an overall CFS detection rate of 2.059% (1.903% in males, 2.234% in females), with prevalence increasing stepwise across academic stages from 1.012% in grade 7 to a peak of 3.728% in cram school students. CFS severity negatively correlated with physical endurance performance on 800m/1000m running tests across both genders, with female cram school students exhibiting significantly reduced vital capacity. The findings provide large-scale epidemiological evidence of adolescent fatigue burden and its link to academic stress and physical performance deficits. Limitations include a cross-sectional questionnaire screening design subject to self-report bias and specific regional applicability to secondary school populations in Shaanxi Province.
Sources:
2026-08-04 - Registry modelling positions muscle symptoms as a central bridge in ME/CFS symptom architecture
A cross-sectional modeling preprint by Habermann-Horstmeier and Horstmeier on Research Square analyzed 745 patients with ME/CFS from the German APAV-ME/CFS registry. Extending the authors’ earlier sex- and menopause-stratified analyses, structural equation modeling identified muscle symptoms—including weakness, myalgia, and fasciculations—as a central bridge linking respiratory, flu-like, and thermoregulatory complaints into a single latent physiological dysregulation factor. Cardiovascular symptoms and visual disturbances further loaded directly onto the muscle-associated construct in reduced physiological models, while factor weightings varied significantly by sex and menopausal status. These statistical findings support the concept that neuromuscular symptoms in ME/CFS reflect integrated systemic neuroimmune and autonomic dysregulation rather than isolated peripheral deconditioning. As a non-peer-reviewed preprint relying on self-reported registry questionnaires without objective muscle biopsies or CPET ergometry, the study is limited by potential recall bias and the underrepresentation of severe, bedbound patients unable to complete digital surveys.
Sources:
2026-08-08 - Japanese PSCORE-J registry reports 34.1% neurological symptoms and 52.9% work discontinuation in post-COVID condition
A peer-reviewed nationwide registry study from the Japanese PSCORE-J initiative, published in General Hospital Psychiatry, characterized clinical and patient-reported outcomes in Post-COVID-19 Condition across 806 online participants and 136 in-person clinic patients. Neurological manifestations were the most frequent clinical presentation at 34.1%, followed by pain-related symptoms at 23.5%, accompanied by a 52.9% rate of work discontinuation. Longer acute infection duration and social isolation were significant predictors of higher composite physical and psychological symptom burden in both sexes. Although the study highlights the heavy socioeconomic and neurological toll of post-viral illness in East Asia, it evaluated a broad PASC cohort without ME/CFS case definitions or post-exertional malaise screening. Additional limitations include the disproportionately small size of the in-person clinical cohort relative to the online sample, the exclusion of bedbound individuals from in-person testing, and the fact that sex-stratified interaction differences did not achieve statistical significance.
Sources:
2026-08-11 - Meta-analysis estimates 37% pooled IBS prevalence in ME/CFS
A peer-reviewed systematic review and meta-analysis published in Frontiers in Medicine evaluated the comorbidity between ME/CFS and irritable bowel syndrome across 22 studies, including 18 in quantitative synthesis. The meta-analysis established a significant 7.20-fold increased odds of IBS in patients with ME/CFS compared to non-fatigued controls (OR 7.20, 95% CI: 2.77–18.76). The pooled prevalence of IBS across ME/CFS cohorts was estimated at 37% (95% CI: 23%–54%), confirming gastrointestinal disturbance as a major co-occurring clinical feature. However, substantial statistical heterogeneity was observed across included studies due to disparate ME/CFS case criteria and evolving Rome diagnostic definitions for IBS. The analysis relies on observational data that cannot establish whether gut dysfunction precedes, accompanies, or arises secondary to ME/CFS, and severe or bedbound patients were not systematically differentiated in the underlying literature.
Sources:
2026-08-14 - Archival analysis traces how ME and CFS case definitions were built between 1950 and 1990
A peer-reviewed sociohistorical analysis published in Medical Humanities examined how biomedical institutions constructed case definitions for myalgic encephalomyelitis and chronic fatigue syndrome between 1950 and 1990. The archival study traced the divergent origins of UK outbreak investigations of epidemic ME and the late-1980s US CDC consensus panels that formulated the initial CFS criteria. The author argued that health institutions systematically managed biomedical uncertainty by regulating diagnostic boundaries and producing epistemic obscurity around post-infectious disability. This analysis provides important institutional context for why diagnostic definitions remain historically contentious and how administrative categorizations shaped clinician skepticism and patient stigma. As a qualitative medical humanities work, the study contains no empirical biological or clinical cohort data and does not assess contemporary biomarker developments or post-2015 case definitions.
Sources:
2026-08-15 - Bioethics paper extends epistemic injustice to affective injustice in ME/CFS care
A peer-reviewed bioethics analysis by Sven Walter in Medicine, Health Care and Philosophy examined the systemic harms of clinical disbelief in ME/CFS care. Moving beyond epistemic injustice—where patients are dismissed as unreliable informants—the paper introduced the concept of affective injustice to describe how institutional disbelief polices and distorts patients’ emotional lives. The author outlined structural mechanisms including the pathologization of legitimate distress as psychiatric illness, the denial of emotional validation by clinicians, and the forced emotional labor required of patients to appear calm and compliant to secure basic care. This framework articulates how medical skepticism imposes an unacknowledged psychological and iatrogenic burden that compounds the physical severity of ME/CFS. As a conceptual philosophical analysis, the paper provides no empirical cohort datasets, biological biomarkers, or therapeutic evaluations, and should not be interpreted as clinical trial evidence.
Sources:
2026-08-16 - ME/CFS Research Foundation report maps the top 100 interventional PAIS trials
A research landscape white paper authored by Dr. Fred Dejonckheere and published by the ME/CFS Research Foundation mapped and categorized the top 100 interventional clinical trials across Post-Acute Infection Syndromes (PAIS). Covering ME/CFS, Long COVID, POTS, fibromyalgia, and post-treatment Lyme disease, the report classified ongoing and completed trials by targeted mechanisms, including viral persistence, autoimmunity, metabolic failure, and vascular dysfunction. The analysis documented that the vast majority of active trials remain investigator-initiated academic studies, highlighting a severe deficit in commercial biopharmaceutical investment relative to disease burden. It also emphasized the urgent infrastructural need for biomarker-driven patient stratification and standardized clinical endpoints to facilitate regulatory drug approval across post-viral conditions. As a non-peer-reviewed foundation report compiling registry listings, the publication does not independently audit trial conduct or efficacy outcomes, encompasses broad PAIS cohorts lacking ME/CFS-specific stratification, and claims no direct therapeutic validation.
Sources: